CURRENT
ISSUE
1607
September 21, 2020

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with those of COVID-19. Available vaccines and recommendations for specific patient populations for the 2020-2021 season are listed in Tables 2 and 3. Lower rates of influenza illness have been observed this season in the Southern Hemisphere, probably because of masking, social distancing, school closures, and travel restrictions.2

TIMING...  Continue reading

More from Issue 1607
Previous Issue: 1606      September 7, 2020
Coming Soon
Drugs for Migraine
Lyumjev and Semglee - Two New Insulins for Diabetes
Minocycline Foam (Zilxi) for Rosacea
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
FROM
ISSUE
1607

Esketamine (Spravato – Janssen), an intranasal N-methyl-D-aspartate (NMDA) receptor antagonist that was previously approved by the FDA for treatment-resistant depression,1 has now been approved for treatment of depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior. Esketamine is the S-enantiomer of the anesthetic ketamine (Ketalar, and generics). It is the first drug to ... Continue reading

 Tweets